NEW YORK, Sept. 28 (GenomeWeb News) - Nanogen expects to raise nearly $20 million through a stock offering to institutional investors scheduled to close today, the company said.
The San Diego-based company will sell 6.8 million shares of its common stock to investors at a price of nearly $3 per share, with 1 million warrants exercisable at $4 per share for five years.
Already have a GenomeWeb or 360Dx account?Login Now.
In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.
The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.
Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.
In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.